-
Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial.
Shindo M, Chayama K, Mochida S, Toyota J, Tomita E, Kumada H, Yokosuka O, Sata M, Hayashi N, Suzuki K, et al.
Hepatol Int. 2009 May 23; . Epub 2009 May 23.
[Hepatol Int. 2009]
-
ReviewDNA-guided hepatitis B treatment, viral load is essential, but not sufficient.
Bárcena Marugán R, García Garzón S.
World J Gastroenterol. 2009 Jan 28; 15(4):423-30.
[World J Gastroenterol. 2009]
-
Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma.
Llovet JM, Lok A.
J Natl Cancer Inst. 2008 Aug 20; 100(16):1121-3. Epub 2008 Aug 11.
[J Natl Cancer Inst. 2008]
- » See all...